Pasithea Therapeutics Corp.
KTTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $182 | $0 | $0 | $162 |
| Gross Profit | -$182 | $0 | $0 | -$162 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,358 | $2,149 | $1,730 | $1,510 |
| G&A Expenses | $0 | $1,662 | $1,950 | $0 |
| SG&A Expenses | $1,571 | $1,662 | $1,950 | $1,587 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Expenses | $2,929 | $3,811 | $3,680 | $3,097 |
| Operating Income | -$3,110 | -$3,811 | -$3,680 | -$3,260 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $73 | $95 | $117 | $82 |
| Pre-Tax Income | -$3,037 | -$3,716 | -$3,563 | -$3,178 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,037 | -$3,716 | -$3,563 | -$3,178 |
| % Margin | – | – | – | – |
| EPS | -0.41 | -0.66 | -3.25 | -2.9 |
| % Growth | 37.9% | 79.7% | -12.1% | – |
| EPS Diluted | -0.41 | -0.66 | -3.25 | -2.9 |
| Weighted Avg Shares Out | 7,444 | 5,641 | 1,096 | 1,096 |
| Weighted Avg Shares Out Dil | 7,444 | 5,641 | 1,096 | 1,096 |
| Supplemental Information | – | – | – | – |
| Interest Income | $43 | $54 | $47 | $80 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $182 | $162 | $162 | $162 |
| EBITDA | -$2,856 | -$3,649 | -$3,518 | -$3,015 |
| % Margin | – | – | – | – |